U.S. and Canada Embark on Project to Develop a Gene Therapy for Retinal Blindness
The goal of this project is to begin testing a new gene therapy in patients who are losing their vision due to retinal disease, by the end of five years,” said Dr. Tsilflidis, Senior Scientist at the Ottawa Hospital Research Institute and Associate Professor in the Faculty of Medicine at the University of Ottawa. By blocking a process (apoptosis) that causes retinal cell death, thus blindness, the XIAP gene therapy protects the retinal cells. The gene is delivered to the eye using a virus.
If you found this article interesting, you can get updates in your email inbox any time similar articles are posted. The subscription options you will be presented with are based on your interest in this article. Just click here to sign up for a free membership and get started!